(Q37417441)

20 August 2017

Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience (English)

1 reference

20 August 2017

phase I clinical trial

0 references

1 reference

12

Razelle Kurzrock

1 reference

Apostolia Maria Tsimberidou

20 August 2017

1

object named as

Apostolia Maria Tsimberidou

1 reference

20 August 2017

7

Aung Naing

1 reference

20 August 2017

Christos Vaklavas

2

1 reference

20 August 2017

Sijin Wen

3

1 reference

20 August 2017

David Hong

4

1 reference

20 August 2017

Jennifer Wheler

5

1 reference

20 August 2017

Chaan Ng

6

1 reference

20 August 2017

Susan Tse

8

1 reference

20 August 2017

Naifa Busaidy

9

1 reference

20 August 2017

Maurie Markman

10

1 reference

20 August 2017

Steven I Sherman

11

1 reference

20 August 2017

language of work or name

English

0 references

publication date

9 October 2009

1 reference

The Journal of Clinical Endocrinology and Metabolism

20 August 2017

1 reference

20 August 2017

94

1 reference

20 August 2017

11

1 reference

20 August 2017

4423-4432

1 reference

Phase II trial of sorafenib in metastatic thyroid cancer

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Genetic mutations in thyroid carcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Motesanib diphosphate in progressive differentiated thyroid cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Phase II trial of sorafenib in advanced thyroid cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Thyroid carcinoma: molecular pathways and therapeutic targets

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

6 September 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

New therapeutic approaches to treat medullary thyroid carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Investigational therapies for metastatic thyroid carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

New therapeutic approaches for metastatic thyroid carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

A phase II study of gefitinib in patients with advanced thyroid cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2775645

Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer

2 September 2018

1 reference

12 December 2020

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas

1 reference

12 December 2020

A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma

1 reference

12 December 2020

Anaplastic thyroid cancer

1 reference

12 December 2020

Identifiers

DOI

10.1210/JC.2009-0743

1 reference

release_ckvis4acufhf5d6cafuq5t5434

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ckvis4acufhf5d6cafuq5t5434

24 November 2022

mapped directly with Wikidata item

1 reference

20 August 2017

PubMed publication ID

19820016

1 reference